Human or animal specimens for which there is minimal likelihood that pathogens are present are not subject to ADR if the specimen is carried in a packaging which will prevent any leakage and which is marked with the words "Exempt human specimen" or "Exempt animal specimen", as appropriate.

The packaging is deemed to complywith the above requirements if it meets the following conditions:

(a)The packaging consists of three components:
(i)a leak-proof primary receptacle(s);
(ii)a leak-proof secondary packaging; and
(iii)an outer packaging of adequate strength for its capacity, mass and intended use, andwith at least one surface having minimum dimensions of 100mm× 100mm;

(b)For liquids, absorbent material in sufficient quantity to absorb the entire contents is placedbetween the primary receptacle(s) and the secondary packaging so that, during carriage, anyrelease or leak of a liquid substance will not reach the outer packaging and will notcompromise the integrity of the cushioning material;

(c)When multiple fragile primary receptacles are placed in a single secondary packaging, they areeither individually wrapped or separated to prevent contact between them.

NOTE1:An element of professional judgment is required to determine if a substance is exempt under this paragraph. That judgment should be based on the known medical history, symptoms and individual circumstances of the source, human or animal, and endemic local conditions. Examples of specimens which may be carried under this paragraph include the blood or urine tests to monitor cholesterol levels, blood glucose levels, hormone levels, or prostate specific antibodies (PSA); those required to monitor organ function such as heart, liver or kidney function for humans or animals with non-infectious diseases, or for therapeutic drug monitoring; those conducted for insurance or employment purposes and are intended to determine the presence of drugs or alcohol; pregnancy test; biopsies to detect cancer; and antibody detection in humans or animalsin the absence of any concern for infection (e.g. evaluation of vaccine induced immunity, diagnosis of autoimmune disease, etc.).

NOTE2:For air transport, packagings for specimens exempted under this paragraph shall meet the conditions in (a) to (c).

Except for:

(a)Medical waste (UN No. 3291);

(b)Medical devices or equipment contaminated with or containing infectious substances inCategory A (UN No. 2814 or UN No. 2900); and

(c)Medical devices or equipment contaminated with or containing other dangerous goods thatmeet the definition of anotherclass,

medicaldevices or equipment potentially contaminated with or containing infectious substances which are being carried for disinfection, cleaning, sterilization, repair, or equipment evaluation are not subject to provisions of ADRother than those of this paragraph if packed in packagings designed and constructed in such a way that, under normal conditions of carriage, they cannot break, be punctured or leak their contents. Packagings shall be designed to meet the construction requirements listed in 6.1.4 or 6.6.4.

These packagings shall meet the general packing requirements of 4.1.1.1 and 4.1.1.2 and be capable of retaining the medical devices and equipment when dropped from a height of 1.2 m.

The packagings shall be marked "USED MEDICAL DEVICE" or "USED MEDICALEQUIPMENT". When using overpacks, these shall be marked in the same way, except when the inscription remains visible.

Medical or clinical wastes containing Category A infectious substances shall be assigned to UNNo. 2814or UNNo. 2900 as appropriate. Medical or clinical wastes containing infectious substances in CategoryB shall be assigned to UNNo. 3291.

NOTE:Medical or clinical wastes assigned to number 180103 (Wastes from human or animal health care and/or related research – wastes from natalcare, diagnosis, treatment or prevention of disease in humans – wastes whose collection and disposal is subject to special requirements in order to prevent infection) or 180202 (Wastes from human or animal health care and/or related research – wastes from research, diagnosis, treatment or prevention of disease involving animals – wastes whose collection and disposal is subject to special requirements in order to prevent infection) according to the list of wastes annexed to the Commission Decision 2000/532/EC4as amended, shall be classified according to the provisions set out in this paragraph, based on the medical or veterinary diagnosis concerning the patient or the animal.

Medical or clinical wastes which are reasonably believed to have alow probability of containing infectious substances shall be assigned to UN No. 3291. For the assignment, international, regional or national waste catalogues may be taken into account.

NOTE 1:The proper shipping name for UN No. 3291 is "CLINICAL WASTE,UNSPECIFIED, N.O.S." or "(BIO) MEDICAL WASTE, N.O.S". or "REGULATED MEDICAL WASTE, N.O.S.".

NOTE 2:Notwithstanding the classification criteria set out above, medical or clinical wastes assigned to number 1801 04 (Wastes from human or animal health care and/or related research – wastes from natal care, diagnosis, treatment or prevention of disease in humans – wastes whose collection and disposal is not subject to special requirements in order to prevent infection) or 180203 (Wastes from human or animal health care and/or related research – wastes from research, diagnosis, treatment or prevention of disease involving animals – wastes whose collection and disposal is not subject to special requirements in order to prevent infection) according to the list ofwastes annexed to the Commission Decision 2000/532/EC5as amended, are not subject to the provisions of ADR.

Decontaminated medical or clinical wastes which previously contained infectious substances are not subject to the provisions of ADRunless they meet the criteria for inclusion in another class.

Medical or clinical wastes assigned to UN No. 3291 are assigned to packing groupII.

Unless an infectious substance cannot be consigned by any other means, live animals shall not be used to consign such a substance. A live animal which has been intentionally infected and is known or suspected to contain an infectious substance shall only be carried under terms and conditions approved by the competent authority.NOTE:The approval of the competent authorities shall be issued on the basis of the relevant rules for the carriage of live animals, taking into consideration dangerous goods aspects. The authorities

_____________________
4   Commission Decision 2000/532/EC of 3 May 2000 replacing Decision 94/3/EC establishing a list of wastes pursuant to Article 1(a) of Council Directive 75/442/EEC on waste (replaced by the Directive 2006/12/EC of the European Parliament and of the Council (Official Journal of the European Union No. L114 of 27 April 2006, page 9)) and Council Decision 94/904/EC establishing a list of hazardous waste pursuant to Article 1(4) of Council Directive 91/689/EEC on hazardous waste (Official Journal of the European Communities No. L 226 of 6 September 2000, page3). 

that are competent to lay down these conditions and rules for approval shall be regulated at national level.

If there is no approval by a competent authority of a Contracting Party to ADR, the competent authority of a Contracting Party to ADR may recognize an approval issued by the competent authority of a country that is not a Contracting Party to ADR.

Rules for the carriage of livestock are, for example, contained in Council Regulation (EC) No1/2005 of 22December 2004 on the protection of animals during transport (Official Journal of the European UnionNo L3 of 5January 2005) as amended.